10:20 AM EDT, 03/10/2025 (MT Newswires) -- Agilent Technologies ( A ) said Monday that its PD-L1 IHC 28-8 pharmDx kit was approved for two new companion diagnostic indications in the European Union.

The kit is now approved as a companion diagnostic test for malignant melanoma and non-small cell lung cancer, Agilent ( A ) said.

The new approvals bring the kit's total approved indications in Europe to nine, the company said.

Price: 123.91, Change: -2.79, Percent Change: -2.20